Taxotere News and Research

RSS

Taxotere is a drug used together with other drugs to treat certain types of breast cancer, stomach cancer, prostate cancer, and certain types of head and neck cancer. It is also being studied in the treatment of other types of cancer. Taxotere is a type of mitotic inhibitor. Also called docetaxel.

Alimta receives positive endorsement for lung cancer approval from FDA Advisory Committee

Eli Lilly and Company have announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration positively endorsed Alimta® (pemetrexed), an antifolate, for accelerated approval in the second-line treatment of non-small cell lung cancer.

29 Jul 2004

Strategic analysis of the breast cancer therapeutics pipeline

Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.

15 Jul 2004

European Commission has approved the use of Herceptin® (trastuzumab) in combination with Taxotere®

The approval is based on study results which showed that for women with HER2-positive breast cancer, the combination of Herceptin and Taxotere significantly improved median life expectancy by more than one-third (31 months with Herceptin plus Taxotere vs. 22 months for Taxotere alone).

23 Jun 2004

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Investigational drug Abraxane™ (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol®) and/or docetaxel (Taxotere®).

15 Jun 2004

Docetaxel decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy

Johns Hopkins Kimmel Cancer Center clinicians were among those at leading institutions that have completed a three-year international study showing that docetaxel, a drug made from yew tree needles, decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy.

11 Jun 2004

$First drug approved for hormone refractory prostate cancer that has shown a survival benefit$

First drug approved for hormone refractory prostate cancer that has shown a survival benefit

The the Food and Drug Administration (FDA) approved Taxotere (docetaxel), injection in combination with prednisone ( a steroid), for the treatment of patients with advanced metastatic prostate cancer. This is the first drug approved for hormone refractory prostate cancer that has shown a survival benefit.

19 May 2004

Drug combo effective for advanced breast cancer

A pair of studies at UCLA's Jonsson Cancer Center that takes laboratory science to the patients' bedside found that combining the molecularly targeted therapy Herceptin with a specific chemotherapy combination resulted in significant tumor response rates and longer relapse-free periods in women with an aggressive form of advanced breast cancer.

19 May 2004

Australian company receives FDA orphan drug designation for product to treat malignant melanomas

Progen Industries Limited, an Australian anti-cancer drug development company, announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for their lead anti-angiogenesis product PI-88 for treatment of malignant melanoma.

3 May 2004

Taxotere News and Research

Further Reading

Alimta receives positive endorsement for lung cancer approval from FDA Advisory Committee

Strategic analysis of the breast cancer therapeutics pipeline

European Commission has approved the use of Herceptin® (trastuzumab) in combination with Taxotere®

Investigational drug Abraxane is active and well tolerated in women with metastatic breast cancer

Docetaxel decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy

First drug approved for hormone refractory prostate cancer that has shown a survival benefit

Drug combo effective for advanced breast cancer

Australian company receives FDA orphan drug designation for product to treat malignant melanomas

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News